Heart Metabolics Receives Funding for US Clinical Development of Heart ... PharmaLive.com (press release) The proceeds of the Series A round will be used to advance U.S. clinical development of the company's lead drug candidate, perhexiline, for the treatment of heart failure symptoms in patients with hypertrophic cardiomyopathy ("HCM"). Investors in the ... |
